Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Genentech Seeks to Block Rituxan Biosimilar Launch in Japan
January 10, 2018
- Lenvima-Keytruda Combo Earns FDA’s Breakthrough Designation for RCC
January 10, 2018
- GSK Canada Head Tapped for Japan President
January 10, 2018
- ALL Med Blinatumomab Filed in Japan: Amgen Astellas
January 10, 2018
- Takeda Snaps Up Cell Therapy Partner TiGenix in GI, Partners with Denali in CNS
January 9, 2018
- Chugai Executes Asset Transfer for 13 Off-Patent Brands
January 9, 2018
- Will Pricing Reform Spur Divestment of Off-Patent Brands in Japan? Next 3 Months Hold Key for Future Directions
January 1, 2018
- Nissui Pharma to Invest in Keio Univ. Spinoff Specializing in Saliva-Based Tests
December 28, 2017
- China FDA Puts Lenvima on Priority Review for HCC
December 28, 2017
- Sumitomo Dainippon Begins Japan PIII for Poxel’s Diabetes Med
December 28, 2017
- Generic Use Rate at 68.8% in July-September: JGA
December 27, 2017
- Sawai Shooting for 12.7% Annual Growth for Upsher-Smith: Exec
December 27, 2017
- Otsuka Group to Invest 1 Billion Yen in Kyoto Startup, Aims to Commercialize iPS Cell-Derived Platelets
December 26, 2017
- Maruho Grabs Global Rights to RaQualia’s Sodium Channel Blocker
December 26, 2017
- MHLW to Use Its Classification Table to Pick PMP-Eligible Similar Drugs; How Will 3 Year 3rd Product Rule Affect I/O and Other Meds?
December 26, 2017
- 86 Apply for Voluntary Redundancy for Manufacturing Jobs: Sumitomo Dainippon
December 26, 2017
- TB Vaccine Joint Venture to Be Dissolved: Sumitomo Dainippon, Japan BCG, INCJ
December 26, 2017
- Kyowa Kirin Taps Miyamoto as President and COO
December 25, 2017
- Opdivo Filed for Dosage Change, Label Expansion in Japan
December 25, 2017
- Eisai/Biogen’s Alzheimer’s Candidate BAN2401 Disappoints in PII
December 25, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…